Levin W, Wood A W, Chang R L, Kumar S, Yagi H, Jerina D M, Lehr R E, Conney A H
Cancer Res. 1983 Oct;43(10):4625-8.
Benz[c]acridine (B[c]ACR) and 12 of its derivatives, including the 5 metabolically possible trans-dihydrodiols, the diastereomeric bay-region diol-epoxides, 2 non-bay-region diol-epoxides, and the K-region arene oxide, were tested for tumor-initiating activity on mouse skin. A single topical application of 0.4 to 2.5 mumol of compound was followed 12 days later by twice-weekly applications of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate for 25 weeks. B[c]ACR was a weak tumor initiator on mouse skin, producing a 37% tumor incidence and 1.33 tumors/mouse at the 2.5-mumol dose. Of the five metabolically possible trans-dihydrodiols of B[c]ACR, only trans-3,4-dihydroxy-3,4-dihydro-B[c]ACR had significant tumor-initiating activity. This compound was at least 6-fold more active than was the parent compound at the three doses tested. The diastereomeric bay-region diol-epoxides, in which the epoxide oxygen is either cis(isomer 1) or trans (isomer 2) to the benzylic hydroxyl group, each had significant tumor-initiating activity, although isomer 2 was at least 5-fold more active than was isomer 1 and had activity equal to that of its potential metabolic precursor, trans-3,4-dihydroxy-3,4-dihydro-B[c]ACR. Two non-bay-region diol-epoxides (isomer 2 of the 8,9-diol-10,11-epoxide and the 10,11-diol-8,9-epoxide) and the 5,6-arene oxide (K-region) were inactive at the doses tested. 3,4-Dihydro-B[c]ACR, the potential metabolic precursor of a bay-region tetrahydroepoxide, was the most potent tumor initiator analyzed in the present study. At an initiating dose of 0.4 mumol, this compound produced a 97% tumor incidence and 7.90 tumors/mouse after 15 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate. These results suggest that B[c]ACR, the N-12 analogue of benz[a]anthracene, undergoes metabolic activation to an ultimate carcinogenic metabolite via formation of a bay-region diol-epoxide, as has already been demonstrated for benz[a]anthracene.
对苯并[c]吖啶(B[c]ACR)及其12种衍生物进行了小鼠皮肤肿瘤起始活性测试,这些衍生物包括5种代谢上可能的反式二氢二醇、非对映体的湾区二醇环氧化物、2种非湾区二醇环氧化物以及K区芳烃氧化物。将0.4至2.5 μmol的化合物单次局部涂抹于小鼠皮肤上,12天后,每周两次涂抹肿瘤促进剂12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯,持续25周。B[c]ACR是一种弱的小鼠皮肤肿瘤起始剂,在2.5 μmol剂量下,肿瘤发生率为37%,每只小鼠产生1.33个肿瘤。在B[c]ACR的5种代谢上可能的反式二氢二醇中,只有反式 - 3,4 - 二羟基 - 3,4 - 二氢 - B[c]ACR具有显著的肿瘤起始活性。在测试的三个剂量下,该化合物的活性至少是母体化合物的6倍。非对映体的湾区二醇环氧化物,其中环氧氧与苄基羟基呈顺式(异构体1)或反式(异构体2),均具有显著的肿瘤起始活性,尽管异构体2比异构体1的活性至少高5倍,且其活性与其潜在的代谢前体反式 - 3,4 - 二羟基 - 3,4 - 二氢 - B[c]ACR相当。两种非湾区二醇环氧化物(8,9 - 二醇 - 10,11 - 环氧化物的异构体2和10,11 - 二醇 - 8,9 - 环氧化物)以及5,6 - 芳烃氧化物(K区)在测试剂量下无活性。3,4 - 二氢 - B[c]ACR是湾区四氢环氧化物的潜在代谢前体,是本研究中分析的最有效的肿瘤起始剂。在起始剂量为0.4 μmol时,用12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯促进15周后,该化合物的肿瘤发生率为97%,每只小鼠产生7.90个肿瘤。这些结果表明,苯并[a]蒽的N - 12类似物B[c]ACR通过形成湾区二醇环氧化物代谢活化成最终致癌代谢物,这已在苯并[a]蒽中得到证实。